BBIXF.US Bonus BioGroup Ltd

Healthcare Biotechnology USA Stocks
0.0400 USD
Close of Nov 12, 2026
0.0200 0.1500
Market cap
USD 46.7M
P/E
-
P/B
10.44x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BBIXF.US undervalued?

Graham number

The Graham number of Bonus BioGroup Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bonus BioGroup Ltd fundamental analysis

No fundamental analysis for Bonus BioGroup Ltd yet.

Bonus BioGroup Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bonus BioGroup Ltd

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the …

Full company profile